Frederic Chiambaretta
Research Subjects
Frederic Chiambaretta has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Daruich
Ophthalmology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris Cité University, Paris, France
1 shared publication Anders Behndig
Department of Clinical Science/Ophthalmology, Umeå University Hospital, Umeå, Sweden
1 shared publication- Aurélien Mulliez
Direction de le Recherche Clinique et de l’Innovation, Centre Hospitalier Universitaire de Clermont-Ferrand, 63000 Clermont Ferrand, France
1 shared publication Carlos Aguiar
Hospital de Santo Antonio, Porto, Portugal
1 shared publication- Christophe Baudouin
Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, IHU FOReSIGHT, Paris, France
1 shared publication - Dominique Bremond-Gignac
Ophthalmology Department, Necker-Enfants Malades University Hospital, AP-HP, OPHTARA Rare Eye Disease Center, Paris Cité University, Paris, France
1 shared publication
Latest Publications
- 1 August 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Peripheral Ulcerative Keratitis in VEXAS Syndrome
- 1 August 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Peripheral Ulcerative Keratitis in VEXAS Syndrome
- 15 October 2019
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 28 (11) , 1013-1020
Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers
Introduction: Corneal ulcers normally resolve spontaneously because of the proliferative ability of the corneal epithelium; however, sometimes, epithelial healing is diminished, even when standard treatments are administered. Hence, the treatment of refractory corneal ulcers is challenging and is the subject of ongoing efforts in preclinical and clinical development. Emerging treatment approaches include thymosine β4, CODA001 and topical insulin. Cenegermin eye drops, containing recombinant human nerve growth factor and ReGenerating Agent, a matrix therapy agent, have recently been commercialized for the treatment of moderate to severe neurotrophic keratitis in adults. Areas covered: We describe emerging therapeutic approaches for the management of refractory corneal ulcers and treatments recently introduced to the market. Pubmed and Clinicaltrial.gov databases were first searched including the terms: “corneal ulcer” or “neurotrophic keratopathy” and “treatment”. Each treatment was searched in the same databases separately. Expert opinion: Affections of the sensory corneal nerves are the main factor contributing to the pathophysiology of neurotrophic keratopathy; this explains the healing difficulties of this form of ulcer. Cenegermin is a promising therapy acting as a neurotrophic agent for corneal healing. ReGenerating Agent has led to rapid pain relief and corneal healing, but randomized clinical trials are still necessary for further assessment.
- 15 October 2019
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 28 (11) , 1013-1020
Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers
Introduction: Corneal ulcers normally resolve spontaneously because of the proliferative ability of the corneal epithelium; however, sometimes, epithelial healing is diminished, even when standard treatments are administered. Hence, the treatment of refractory corneal ulcers is challenging and is the subject of ongoing efforts in preclinical and clinical development. Emerging treatment approaches include thymosine β4, CODA001 and topical insulin. Cenegermin eye drops, containing recombinant human nerve growth factor and ReGenerating Agent, a matrix therapy agent, have recently been commercialized for the treatment of moderate to severe neurotrophic keratitis in adults. Areas covered: We describe emerging therapeutic approaches for the management of refractory corneal ulcers and treatments recently introduced to the market. Pubmed and Clinicaltrial.gov databases were first searched including the terms: “corneal ulcer” or “neurotrophic keratopathy” and “treatment”. Each treatment was searched in the same databases separately. Expert opinion: Affections of the sensory corneal nerves are the main factor contributing to the pathophysiology of neurotrophic keratopathy; this explains the healing difficulties of this form of ulcer. Cenegermin is a promising therapy acting as a neurotrophic agent for corneal healing. ReGenerating Agent has led to rapid pain relief and corneal healing, but randomized clinical trials are still necessary for further assessment.
- Open Access
- 1 May 2019
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 13, 811-819
Systemic exposure to intracameral vs topical mydriatic agents: in cataract surgery
Objective: The objective of this study was to compare systemic exposure to tropicamide/phenylephrine following intracameral or topical administration before cataract surgery. Patients and methods: Mydriatics exposure was calculated in patients randomized to intracameral fixed combination of mydriatics and anesthetic ([ICMA]: tropicamide 0.02%, phenylephrine 0.31%, and lidocaine 1%, N=271) or mydriatic eye drops ([EDs]: tropicamide 0.5% and phenylephrine 10%, N=283). Additional doses were permitted if required. Mydriatic plasma levels were determined by mass spectrometric HPLC in 15 patients per group before and after administration. Results: Most ICMA patients (73.6%) received a single dose (200 µL) representing an exposure to tropicamide of 0.04 mg and phenylephrine of 0.62 mg. None of these patients received additional mydriatics. In the control group (three administrations), the exposure was 0.45 (11.3-fold higher than ICMA) and 10.2 (16.5-fold higher) mg. When additional ED was used in this group (9.2% of patients), it was 37.5-fold higher for tropicamide (10 drops, 1.5 mg) and 54.8-fold higher for phenylephrine (10 drops, 34 mg) than the recommended ICMA dose. Tropicamide plasma levels were not detectable at any time point in ICMA patients while it was detectable in all ED patients at 12 and 30 minutes. Phenylephrine was detectable in 14.3% of ICMA patients compared to all ED patients at least at one time point. More ED patients experienced a meaningful increase in blood pressure and/or heart rate (11.2% vs 6.0% of ICMA patients; P=0.03). Conclusion: Systemic exposure to tropicamide/phenylephrine was lower and cardiovascular (CV) effects were less frequent with ICMA. This could be of particular significance in patients at CV risk.
- 1 May 2019
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 13, 811-819
Open AccessSystemic exposure to intracameral vs topical mydriatic agents: in cataract surgery
Objective: The objective of this study was to compare systemic exposure to tropicamide/phenylephrine following intracameral or topical administration before cataract surgery. Patients and methods: Mydriatics exposure was calculated in patients randomized to intracameral fixed combination of mydriatics and anesthetic ([ICMA]: tropicamide 0.02%, phenylephrine 0.31%, and lidocaine 1%, N=271) or mydriatic eye drops ([EDs]: tropicamide 0.5% and phenylephrine 10%, N=283). Additional doses were permitted if required. Mydriatic plasma levels were determined by mass spectrometric HPLC in 15 patients per group before and after administration. Results: Most ICMA patients (73.6%) received a single dose (200 µL) representing an exposure to tropicamide of 0.04 mg and phenylephrine of 0.62 mg. None of these patients received additional mydriatics. In the control group (three administrations), the exposure was 0.45 (11.3-fold higher than ICMA) and 10.2 (16.5-fold higher) mg. When additional ED was used in this group (9.2% of patients), it was 37.5-fold higher for tropicamide (10 drops, 1.5 mg) and 54.8-fold higher for phenylephrine (10 drops, 34 mg) than the recommended ICMA dose. Tropicamide plasma levels were not detectable at any time point in ICMA patients while it was detectable in all ED patients at 12 and 30 minutes. Phenylephrine was detectable in 14.3% of ICMA patients compared to all ED patients at least at one time point. More ED patients experienced a meaningful increase in blood pressure and/or heart rate (11.2% vs 6.0% of ICMA patients; P=0.03). Conclusion: Systemic exposure to tropicamide/phenylephrine was lower and cardiovascular (CV) effects were less frequent with ICMA. This could be of particular significance in patients at CV risk.
- 1 March 2017
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 100, 230-237
Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions
- 1 March 2017
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 100, 230-237
Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions
- 1 January 2015
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 38 (1) , 22-33
DSAEK après échec de kératoplastie perforante
- 1 January 2015
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 38 (1) , 22-33
DSAEK après échec de kératoplastie perforante
- 1 December 2014
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 37 (10) , 763-772
Evaluation of an eyelid warming device (Blephasteam®) for the management of ocular surface diseases in France: The ESPOIR study
- 1 December 2014
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 37 (10) , 763-772
Evaluation of an eyelid warming device (Blephasteam®) for the management of ocular surface diseases in France: The ESPOIR study